HBIO vs VTRS · rev $22.7M vs rev $7.27B
Harvard Bioscience Inc (HBIO) versus Viatris Inc (VTRS) — a side-by-side from cached financials, not a winner call.
Harvard Bioscience Inc (HBIO) is a medical instruments & supplies company listed on US.
Viatris Inc (VTRS) is a drug manufacturers - specialty & generic company listed on US.
Latest reported HBIO revenue for 2026-06-30 was $22.7M. Net income was -$2.9M. Revenue was up 9.5% from 2026-03-31 to 2026-06-30. HBIO currently screens at market cap $20.3M.
Latest reported VTRS revenue for 2026-06-30 was $7.27B. VTRS currently screens at market cap $10.83B.
HBIO currently screens at market cap $20.3M. VTRS currently screens at market cap $10.83B.
Not investment advice. Open the HBIO and VTRS stock pages for the full models.
Not investment advice.